TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Adults and children over 6 months old and bodyweight \> 5 kg~* Able to be treated by oral route~* Axillary temperature ≥ 37,5 C or history of fever during the previous 2 days~* Symptomatic biologically confirmed Plasmodium vivax mono-infection, with parasitemia from 250 to 100000 parasites /µl of blood~* Written informed consent of the patients and for children written informed consent of the parents/legal representative for children. Children able to understand the objectives and the risks of the study will sign an assent form.~Exclusion criteria:~* Known project of leaving the investigator site area during the follow-up period (42 days)~* Hypersensitivity to one of the investigational medicinal products or to any of the excipients~* Intake of an antimalarial treatment in the previous 30 days~* History of hepatic and (or) haematological impairment during treatment with amodiaquine~* Blurred vision suggesting a retinopathy~* Presence of at least one danger sign of malaria~* Pregnant or breast-feeding women~* Women with childbearing potential not willing to use an effective contraceptive method(s) for the duration of the study~* Known severe concomitant or underlying disease~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- artesunate/amodiaquine (Type: EXPERIMENTAL): artesunate (AS) / amodiaquine (AQ) as fixed dose combination~1 tablet of AS 25mg/ AQ 67,5mg or AS 50mg/AQ 135mg or AS 100mg/ AQ 270mg or 2 tablets of AS 100mg/ AQ 270mg dose according to bodyweight Once daily 3 days of treatment
- chloroquine (Type: ACTIVE_COMPARATOR): 150mg tablets 25mg/kg in 3 days (10mg/kg on day 1 and 7,5 mg/kg on days 2 and 3) dose according to bodyweight Once daily 3 days of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medically stable men or women 18 to 69 years of age (inclusive)~* Work in any capacity (including physicians and midwives with admitting privileges), volunteer, or student at participating hospital~* Able to read, understand, and respond to questionnaires~* Able to read, understand, and sign an informed consent form~* Available for follow-up for 8 days post-vaccination~* Participants in Part B (repeat administration) of the study must also have participated in the previous randomized control trial of self- versus nurse-administered intradermal influenza vaccine and must have attempted to self-administer the vaccine~Exclusion Criteria:~* Already received 2012-13 influenza vaccine~* History of a severe reaction following influenza vaccination~* Known allergy to components of study vaccines (Intanza® or Vaxigrip®)~* History of Guillain-Barré Syndrome (GBS) within 8 weeks following influenza vaccination~* Acute febrile illness (\>37.9ºC orally) within the past 48 hours (participation may be deferred until recovery for these subjects)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: t

Study Arms:
- Nurse-administered IM (Type: EXPERIMENTAL): Nurse-administered intramuscular influenza vaccine (Vaxigrip, 0.5 mL)
- Self-administered intradermal (Type: EXPERIMENTAL): Self-administered intradermal influenza vaccine (Intanza 0.1 mL)
- Repeat self-administration intradermal (Type: ACTIVE_COMPARATOR): Self-administration of intradermal influenza vaccine (Intanza 0.1 mL) by participants who self-administered an intradermal vaccine in our 2010 study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pregnancy-Related Hypertension: Adherence to a New Type of Monitoring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient must have delivered an infant either at Greenville Memorial Hospital or MUSC and be willing and able to follow-up with her respective institution.~* Patient must have been diagnosed with a hypertensive disorder of pregnancy in the antepartum, intrapartum, or postpartum period.~Exclusion Criteria:~* \<18 years of age~* BMI \>50 (due to limitations in blood pressure cuff size through BabyScripts)~* non English-speaking~* not able to receive phone calls and unlimited texts on cell phone~* not able to download and use Babyscripts phone application

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard care (Type: NO_INTERVENTION): Patient will be scheduled for a blood pressure check in the office 7-10 days postpartum
- Intervention (Type: EXPERIMENTAL): Patient will receive a Babyscripts blood pressure cuff(brand: A\&D Medical) and Babyscripts MyJourney phone app with which to monitor their blood pressures twice daily for 16 days after discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Lifestyle Physical Activity Intervention for Older Sedentary Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* women \> 60 years of age who are Senior Health clinic patients~* health care provider's approval to participate~* ability to speak/read English~* access to a telephone~Exclusion Criteria:~* report participation in a regular physical activity program~* report an unresolved acute illness, such as pneumonia or flu~* fail screening for capacity to provide informed consent~* fail a simple functional screen or are currently nonambulatory~* are unable to complete activities of daily living~* have uncorrectable severe hearing or vision deficits~* have a history of falls in the past 3 months~* have other unforeseen pathology that precludes safe participation

- Gender: FEMALE
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lifestyle Physical Activity Intervention (Type: EXPERIMENTAL): the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer \& LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.
- Information/Attention Comparison (Type: ACTIVE_COMPARATOR): the women will be randomized to either the LPA Intervention or Information/Attention Comparison groups using a permuted block randomization scheme. Participants in both groups will be followed longitudinally with repeated assessments of LPA (accelerometer \& LPA diary), stage of change, and self-efficacy at baseline and 3 and 6 months; and functional health and well-being (SF36) at baseline and 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Evaluation of CARESTREAM Cone Beam Computed Tomography (CBCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject 18 years or older~* Subject has provided informed consent~* Subject is able to be positioned properly in the investigational device and be still during the exam to reduce the potential of motion in the images.~* Subject(s) may have a metal screw, plate or artificial joint~Exclusion Criteria:~* Subject is pregnant~* Not able or willing to provide Informed Consent, or consent is withdrawn~* Not able to collect all required case information~* Subject has a history of high radiation exposure:~* Has undergone radiation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Predicate & Invest.- Cadavers 2D & 3D (Type: EXPERIMENTAL): Radiation - Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT).
- Investigational - Human Subjects 3D (Type: EXPERIMENTAL): Radiation - Human subjects will be imaged with 3D investigational device CARESTREAM Cone Beam Computed Tomography (CBCT) only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The University of Michigan PCOS Intervention Using Nutritional Ketosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* We will include women in one PCOS subtype, those having these two symptoms:~  * Hyperandrogenism - (a) If not on current birth control: hyperandrogenism defined as current elevated total testosterone \>= 50 ng/dL or free androgen index \> 1.5 (ratio of testosterone/SHBG x 100) or severe acne or hirsutism (b) if on current birth control: history from the past 10 years of hyperandrogenism defined as past elevated total testosterone \>= 50 ng/dL or free androgen index \> 1.5 (ratio of testosterone/SHBG x 100) or severe acne or hirsutism~ * oligomenorrhea-anovulation defined as spontaneous intermenstrual periods of ≥ 45 days or a total of ≤ 8 menses per year.~Participants must also be:~* overweight or obese (BMI 25-50)~* be 21-40 years old~* have regular access to the internet~* be able to engage in light physical activity~* willing and able to follow the assigned intervention.~Exclusion Criteria:~* a non-English speaker~* inability to complete baseline measurements~* a substance abuse, mental health, or medical condition that would interfere with participation (such as current chemotherapy)~* pregnant or planning to get pregnant in the next 6 months~* type 1 or type 2 diabetes~* baseline aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 times normal~* baseline renal disease defined as BUN \> 30 mg/dL or serum creatinine \>1.4 mg/dL~* baseline uncorrected thyroid disease (TSH \<0.45 mIU/ML or \>4.5 mIU/ML)~* breastfeeding or less than 6 months post-partum~* planned or history of weight loss surgery~* vegan or vegetarian~* currently enrolled in a weight loss program or other investigative study that might conflict with this research~* taking medications known to cause weight gain or loss~* taking hypoglycemic medications other than metformin or medications known to affect metabolism~* or patients with other etiologies of anovulation and hyperandrogenism, e.g., Cushing's disease, thyroid dysfunction, elevated prolactin levels, signs of congenital adrenal hyperplasia, organic intra cranial lesion such as a pituitary tumor, or suspected adrenal or ovarian tumor secreting androgens.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- complete diet and lifestyle program (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients suffering from a head tremor without (isolated) or with associated~* tremor in any other body parts.~* The HT must be troublesome for the patients (TRS 2 for the head tremor~* severity item).~* Patients never treated with botulinum toxin or not treated with botulinum toxin for this indication for at least 4 months.~* Men or women aged from 18 to 80 years old.~* Social security coverage.~* Ability to provide informed consent.~Exclusion Criteria:~* Patients with tremor from cerebellar syndrome (multiple sclerosis, etc.).~* Patients with a predominant dystonic jerky or myoclonic head tremor using~* the Tsui scale (\>1).~* Oral treatments for HT are allowed but must be stable during the study.~* Any contra-indication to Botulinum toxin.~* Women without efficient contraception.~* Patients under supervision or (legal) guardianship.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- EXPERIMENTAL GROUP (Type: EXPERIMENTAL): Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
- CONTROL GROUP (Type: OTHER): Patients eligible for inclusion will be randomized to one of the two groups:~* Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).~* Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Different Drugs to Control Post Root Canal Treatment Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient reported spontaneous pain moderate to severe, ranging from 50 to 100 mm on a VAS (0-100 mm);~2. Adult patients presented for emergency endodontic treatment with a symptomatic maxillary or mandibular tooth (anterior and premolar) with a pulpal diagnosis of Irreversible pulpitis and normal periapex.~3. Patient choose to have root canal treatment for pain of endodontic origin.~4. The patient presented with American Society of Anesthesiologists (ASA) I or II medical history (ASA 1963).~5. The patient had read and thoroughly understood the pain score level sheet~Exclusion Criteria:~1. Patients below 18 years of age;~2. Analgesic taken within the last 4 hours;~3. History of allergy to NSAIDs, paracetamol or local anaesthetics;~4. History of uncontrolled systemic disease \[gastrointestinal (GI) disorders, oesophageal reflux, active asthma, decreased hepatic function, haemorrhagic disorders, or poorly controlled diabetes mellitus\].~5. Patients currently taking opioids, monoamine oxidase inhibitors, tricyclic antidepresssants, carbamazepine, diuretics, or anticoagulants;~6. There was history of opioid addiction or abuse; and~7. Pregnant or nursing female patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Group I (Type: ACTIVE_COMPARATOR): paracetamol 1000mg
- Group II (Type: EXPERIMENTAL): ibuprofen 600mg + paracetamol 1000mg,
- Group III (Type: EXPERIMENTAL): Mefenamic acid 500mg + Paracetamol 1000mg
- Group IV (Type: EXPERIMENTAL): Diclofenac K 50mg + paracetamol 1000 mg
- Group V (Type: PLACEBO_COMPARATOR): No medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigational and Comparative Study in the Management of Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A confirmed with clinical diagnosis of T2DM with duration at least 7 years to ensure established of micro-vascular complication (DKD).~* females (post-menopause), males with sufficient erectile function.~* Patients on stage 3 DN with evidence of persistent micro-albuminuria. All Abnormal tests of (UACR) must be confirmed in two out of three samples collected over a 6 month period before enrolled in the study.~* (urinary ACR≥30-300mg/g) in 3 consecutive measurements in 6 months period despite treatment with RAAS blockade(ramipril 10 mg ) ACEI or for at least 6 months period before enrollment in the study at maximum recommended tolerated dose.~Exclusion Criteria:Cardiovascular disease: angina, arrhythmias, myocardial Infarction, heart failure (NYHA II -IV), uncontrolled hypertension \> (170 \\100 mm Hg) severe hypotension \< (90\\50 mm Hg), Hearing problem, vision defect, previous episodes of retinal / cerebral hemorrhage, psychiatric disease, thyroid disorders, alcohol abuse, smoking, Hepatic insufficiency (child -Pugh class C), (ALT or AST\>3N), cholestasis, history of chronic inflammatory, immunologic or malignant disease. Acute inflammation or infectious disease in the previous 3 months, taking immunosuppressive treatment, Known allergy to tadalafil or methylxanthine, Use alpha one blockers, use of anti-oxidant drugs three months before enrollment in the study ,medications strongly alter CYP3A4 inducer or inhibitor, use of nitrates, other PDEI drugs, - Renal disease (acute kidney injury, recent exposure to radio- contrast media, creatinine clearance \<30 ml/ min /1.73 m2 , bleeding disorders, peptic ulcer, and stroke, Pregnancy, lactation.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control group (Type: NO_INTERVENTION): : (n=30) control group will receive traditional therapy blood glucose lowering agent +RAAS blockade ACEI or ARBs for six months.
- Tadalafil group (Type: EXPERIMENTAL): :( n=30) will receive traditional therapy +tadalafil PO 20 mg every other day for six months
- pentoxifylline group (Type: EXPERIMENTAL): :( n=30) will receive traditional therapy+ pentoxifylline PO 400 mg twice daily for six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Eplerenone on Cardiovascular Disease in HIV (MIRACLE HIV Study)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ages 40-65 years~2. Antiretroviral use (ART) \>12 months and HIV viral load \<100 copies/mL~3. VAT\> 110cm2~Exclusion Criteria:~1. Antihypertensive use including, ACE Inhibitor, ARB, MR blockade, diuretic, potassium (K) supplementation; or BP\>140/90 mmHg. Stable use (\>3 months) of beta-blockers or calcium channel blockers (CCB) (except verapamil) is allowed.~2. Unstable statin use \<12 months. Stable use (\>12 months) is allowed.~3. Use of full dose ritonavir, nelfinavir, clarithromycin, and other strong inhibitors of CYP3A4, as well as CYP3A4 inducers.~4. Continuous oral steroid use (equivalent to prednisone \> 5 mg daily) within the last 3 months.~5. Uncontrolled diabetes requiring insulin and/or HbA1c \> 7.5%.~6. Creatinine (Cr) \> 1.5 mg/dL or estimated GFR\<60 mL/min/1.73m2.~7. K \> 5.5 mEq/L.~8. Hemoglobin \< 10 g/dL.~9. Known liver disease or ALT \>3x ULN.~10. History of congestive heart failure, stroke, myocardial infarction, or known coronary artery disease.~11. Pregnant, actively seeking pregnancy or breastfeeding.~12. Estrogen, progestin derivative, or other sex steroid use within last 3 months. Stable physiologic testosterone replacement (\> 3 months) is acceptable.~13. Current bacterial or other infections.~14. Active substance abuse.~15. Significant radiation exposure over the course of the year prior to randomization (e.g., radiation therapy, PCI, catheter ablation of arrhythmia) within 12 months of randomization.~16. Previous reaction or contraindication to iodine-containing contrast media and gadolinium.~17. Coronary artery luminal narrowing \>70% on coronary CTA.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Eplerenone (Type: EXPERIMENTAL): Eplerenone 50 mg twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo twice daily along with lifestyle modification (counseling regarding diet and healthy activity) for 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Influence of Dexmedetomidine on a Closed-Loop Anesthesia System

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male patients scheduled for a general anesthesia~Exclusion Criteria:~* age lower than 18 years~* allergy to propofol, or to soja or to peanuts, or to sufentanil, to remifentanil, or to morphine,or to a myorelaxant or to an excipient,~* hypersensibility to sufentanil, or to remifentanil, or to other derivate of fentanyl,~* history of central nervous system disease,~* patients receiving a psychotropic treatment or an agonist-antagonist opiate,~* hypovolemic patients,~* patients receiving a cardio-vascular treatment,~* expected bleeding surgical procedure,~* simultaneous general and loco-regional anesthesia,~* severe hepatic insufficiency.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and a placebo
- dexmedetomidine (Type: EXPERIMENTAL): patients will receive a closed-loop administration of propofol and remifentanil according to bispectral level and dexmedetomidine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete